Try LifeScience Products:
AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
88
K
Drugs & Biologics
46
K
Targets
983
K
Organizations
927
K
/
196
K
Clinical Trials / Results
66
M
Literatures
16
M
Patents
Recent blog posts
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 24
Pharma Frontiers
12 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 24
24 May 2024
May 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Teva and Alvotech Announce the U.S. Release of SIMLANDI® (adalimumab-ryvk) Injection
Latest Hotspot
3 min read
Teva and Alvotech Announce the U.S. Release of SIMLANDI® (adalimumab-ryvk) Injection
24 May 2024
Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Ltd., together with Alvotech, have declared the launch of SIMLANDI (adalimumab-ryvk) injection within the United States.
Read →
Arrowhead Pharma Reveals Strong Gene Knockdown by ARO-RAGE in Asthma Patients
Latest Hotspot
3 min read
Arrowhead Pharma Reveals Strong Gene Knockdown by ARO-RAGE in Asthma Patients
24 May 2024
Arrowhead Pharmaceuticals Unveils New Clinical Data Indicating Significant Gene Knockdown by ARO-RAGE in Asthma Patients.
Read →
Check out our latest report
Global Drug R&D Express (Mar 2024)

Global Drug R&D Express (Mar 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of March totaling 93 drugs. Among them, 2 first-to-market drugs and 2 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Feb 2024)

Global Drug R&D Express (Feb 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 59 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Jan 2024)

Global Drug R&D Express (Jan 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 68 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Who We Serve
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.